Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2006, Article ID 48948, 3 pages
http://dx.doi.org/10.1155/SRCM/2006/48948
Case Report

Relative Hypocalcaemia and Muscle Cramps in Patients Receiving Imatinib for Gastrointestinal Stromal Tumour

Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, United Kingdom

Received 6 July 2005; Accepted 30 December 2005

Copyright © 2006 Jamal M. Zekri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H Joensuu, C Fletcher, S Dimitrijevic, S Silberman, P Roberts, and G Demetri, “Management of malignant gastrointestinal stromal tumours,” The Lancet Oncology, vol. 3, no. 11, pp. 655–664, 2002. View at Publisher · View at Google Scholar
  2. M W Deininger, S G O'Brien, J M Ford, and B J Druker, “Practical management of patients with chronic myeloid leukemia receiving imatinib,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1637–1647, 2003. View at Publisher · View at Google Scholar
  3. S G O'Brien, F Guilhot, R A Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Google Scholar
  4. J Y Blay, S Bonvalot, P Casali et al., “Consensus meeting for the management of gastrointestinal stromal tumors,” Annals of Oncology, vol. 16, no. 4, pp. 566–578, 2005. View at Publisher · View at Google Scholar
  5. G D Demetri, M von Mehren, C D Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar
  6. J Verweij, P G Casali, J Zalcberg et al., “Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial,” The Lancet, vol. 364, no. 9440, pp. 1127–1134, 2004. View at Publisher · View at Google Scholar
  7. M Debiec-Rychter, H Dumez, I Judson et al., “Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma {Group},” European Journal of Cancer, vol. 40, no. 5, pp. 689–695, 2004. View at Publisher · View at Google Scholar
  8. M Talpaz, R T Silver, B J Druker et al., “Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study,” Blood, vol. 99, no. 6, pp. 1928–1937, 2002. View at Publisher · View at Google Scholar
  9. D Marin, S Marktel, M Bua et al., “The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations,” Haematologica, vol. 87, no. 9, pp. 979–988, 2002. View at Google Scholar
  10. J Y Blay, P Berthaud, D Perol et al., “Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized trial of the French Sarcoma Group,” Proceedings of the American Society of Clinical Oncology, vol. 23, 2004, abstract 9006. View at Google Scholar
  11. J L Steegmann, C Alàez, A Granda et al., “Phosphate, calcium balance, and renal function in CML patients previously resistant or intolerant to interferon alpha and treated with STI571,” Blood, vol. 100, 2002, abstract 4815. View at Google Scholar
  12. M Cataldi, A Gaudino, V Lariccia et al., “Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism,” The Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 1, pp. 208–215, 2004. View at Publisher · View at Google Scholar